Which funds bought or sold TWST in Q3 2026?
Twist Bioscience Corp. 5 funds bought, 3 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was +$673M. See also what famous investors say about TWST.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- Fidelity+$965M
- D. E. Shaw+$124M
- Vanguard Capital+$54M
- DurableNEW+$49M
- Polen+$5M
- ARK−$223M
- Baillie Gifford−$73M
- Jennison−$50M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (5)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Fidelity Asset manager | Added+106.2% | +$965M | $1.9B |
| D. E. Shaw Quant & multi-strategy | Added+54% | +$124M | $353M |
| Vanguard Capital Index giant | Added+10.3% | +$54M | $575M |
| Durable Growth / crossover | New | +$49M | $49M |
| Polen Growth / crossover | Added+46.9% | +$5M | $16M |
Sold (3)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| ARK Growth / crossover | Trimmed-25.3% | −$223M | $657M |
| Baillie Gifford Growth / crossover | Trimmed-34.9% | −$73M | $137M |
| Jennison Growth / crossover | Trimmed-56.6% | −$50M | $38M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.